GlaxoSmithKline PLC Director/PDMR Shareholding (0676F)
16 February 2018 - 5:09AM
UK Regulatory
TIDMGSK
RNS Number : 0676F
GlaxoSmithKline PLC
15 February 2018
GlaxoSmithKline plc (the 'Company')
2018 Award under the Deferred Investment Award Programme
Notional Award
On 14 February, 2018 the Company granted an award over notional
Ordinary Shares to a Person Discharging Managerial Responsibilities
('PDMR') under the GlaxoSmithKline Deferred Investment Award
programme.
The PDMR joined the Company in September 2017 and the award is
made under the terms of the employment offer. The award will vest
25% on each of 4 September, 2020, 4 September, 2021, 4 September,
2022, and 4 September, 2023.
Under the programme, awards are made over notional Ordinary
Shares with vesting phased over a specified period to provide
long-term alignment with shareholders. Vesting is subject to the
PDMR not having served the Company notice or having been terminated
by the Company for cause. Notional dividends will accrue on the
award during the vesting period through dividend reinvestment in
additional notional shares. On vesting, the award and accrued
dividends will be paid in cash. Executive Directors are not
eligible to receive awards under the programme.
Transaction notification
1. Details of PDMR/person closely associated
with them ('PCA')
==== =========================================================================
a) Name Mr L Miels
==== ============================ ===========================================
b) Position/status President, Global Pharmaceuticals
==== ============================ ===========================================
c) Initial notification/ Initial Notification
amendment
==== ============================ ===========================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
==== =========================================================================
a) Name GlaxoSmithKline plc
==== ============================ ===========================================
b) LEI 5493000HZTVUYLO1D793
==== ============================ ===========================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument
ISIN: GB0009252882
==== ============================ ===========================================
b) Nature of A restricted award of notional
the transaction Ordinary Shares under the Company's
Deferred Investment Award programme.
==== ============================ ===========================================
c) Price(s) Price(s) Volume(s)
and
volume(s)
==== ============================ ================== ====================
GBP15.00 90,266.667
==================================================== ====================
d) Aggregated n/a (single transaction)
information
====
Aggregated
volume Price
================================================= ===========================
e) Date of the 2018-02-14
transaction
==== ============================ ===========================================
f) Place of n/a
the transaction
==== ============================ ===========================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHVELFFVLFBBBD
(END) Dow Jones Newswires
February 15, 2018 13:09 ET (18:09 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024
